Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 80

1.

The response of Escherichia coli to the alkylating agents chloroacetaldehyde and styrene oxide.

Muenter MM, Aiken A, Akanji JO, Baig S, Bellou S, Carlson A, Conway C, Cowell CM, DeLateur NA, Hester A, Joshi C, Kramer C, Leifer BS, Nash E, Qi MH, Travers M, Wong KC, Hu M, Gou N, Giese RW, Gu AZ, Beuning PJ.

Mutat Res Genet Toxicol Environ Mutagen. 2019 Apr;840:1-10. doi: 10.1016/j.mrgentox.2019.02.001. Epub 2019 Feb 7.

PMID:
30857727
2.

Continuous-wave Thulium Laser for Heating Cultured Cells to Investigate Cellular Thermal Effects.

Miura Y, Pruessner J, Mertineit CL, Kern K, Muenter M, Moltmann M, Danicke V, Brinkmann R.

J Vis Exp. 2017 Jun 30;(124). doi: 10.3791/54326.

3.

Clinical results and toxicity for short-course preoperative radiotherapy and total mesorectal excision in rectal cancer patients.

Sterzing F, Hoehle F, Ulrich A, Jensen A, Debus J, Muenter M.

J Radiat Res. 2015 Jan;56(1):169-76. doi: 10.1093/jrr/rru089. Epub 2014 Oct 23.

4.

The role of perfusion effects in monitoring of chemoradiotherapy of rectal carcinoma using diffusion-weighted imaging.

Ganten MK, Schuessler M, Bäuerle T, Muenter M, Schlemmer HP, Jensen A, Brand K, Dueck M, Dinkel J, Kopp-Schneider A, Fritzsche K, Stieltjes B.

Cancer Imaging. 2013 Dec 11;13(4):548-56. doi: 10.1102/1470-7330.2013.0045.

5.

Intensity modulated radiotherapy (IMRT) combined with concurrent but not adjuvant chemotherapy in primary nasopharyngeal cancer - a retrospective single center analysis.

Saleh-Ebrahimi L, Zwicker F, Muenter MW, Bischof M, Lindel K, Debus J, Huber PE, Roeder F.

Radiat Oncol. 2013 Jan 24;8:20. doi: 10.1186/1748-717X-8-20.

6.

Clinical features, with video documentation, of the original familial lewy body parkinsonism caused by α-synuclein triplication (Iowa kindred).

Gwinn K, Devine MJ, Jin LW, Johnson J, Bird T, Muenter M, Waters C, Adler CH, Caselli R, Houlden H, Lopez G, Singleton A, Hardy J, Singleton A.

Mov Disord. 2011 Sep;26(11):2134-6. doi: 10.1002/mds.23776. Epub 2011 Jun 8. No abstract available.

7.

Local setup errors in image-guided radiotherapy for head and neck cancer patients immobilized with a custom-made device.

Giske K, Stoiber EM, Schwarz M, Stoll A, Muenter MW, Timke C, Roeder F, Debus J, Huber PE, Thieke C, Bendl R.

Int J Radiat Oncol Biol Phys. 2011 Jun 1;80(2):582-9. doi: 10.1016/j.ijrobp.2010.07.1980. Epub 2010 Oct 8.

PMID:
20934279
8.

Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.

Tong J, Wong H, Guttman M, Ang LC, Forno LS, Shimadzu M, Rajput AH, Muenter MD, Kish SJ, Hornykiewicz O, Furukawa Y.

Brain. 2010 Jan;133(Pt 1):172-88. doi: 10.1093/brain/awp282. Epub 2009 Nov 10.

PMID:
19903734
9.

Intraoperative electron radiotherapy for the management of aggressive fibromatosis.

Roeder F, Timke C, Oertel S, Hensley FW, Bischof M, Muenter MW, Weitz J, Buchler MW, Lehner B, Debus J, Krempien R.

Int J Radiat Oncol Biol Phys. 2010 Mar 15;76(4):1154-60. doi: 10.1016/j.ijrobp.2009.03.067. Epub 2009 Aug 3.

PMID:
19647952
10.

Quantitative assessment of image-guided radiotherapy for paraspinal tumors.

Stoiber EM, Lechsel G, Giske K, Muenter MW, Hoess A, Bendl R, Debus J, Huber PE, Thieke C.

Int J Radiat Oncol Biol Phys. 2009 Nov 1;75(3):933-40. doi: 10.1016/j.ijrobp.2009.04.010.

PMID:
19596172
11.

Neoadjuvant chemoradiation in patients with pancreatic adenocarcinoma.

Krempien R, Muenter MW, Harms W, Debus J.

HPB (Oxford). 2006;8(1):22-8. doi: 10.1080/13651820500468034.

12.

Stereotactic single-dose radiotherapy (radiosurgery) of early stage nonsmall-cell lung cancer (NSCLC).

Hof H, Muenter M, Oetzel D, Hoess A, Debus J, Herfarth K.

Cancer. 2007 Jul 1;110(1):148-55.

13.

Randomized phase II--study evaluating EGFR targeting therapy with cetuximab in combination with radiotherapy and chemotherapy for patients with locally advanced pancreatic cancer--PARC: study protocol [ISRCTN56652283].

Krempien R, Muenter MW, Huber PE, Nill S, Friess H, Timke C, Didinger B, Buechler P, Heeger S, Herfarth KK, Abdollahi A, Buchler MW, Debus J.

BMC Cancer. 2005 Oct 11;5:131.

14.

alpha-Synuclein locus triplication causes Parkinson's disease.

Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, Gwinn-Hardy K.

Science. 2003 Oct 31;302(5646):841. No abstract available.

15.

L-DOPA biotransformation: correlations of dosage, erythrocyte catechol O-methyltransferase and platelet SULT1A3 activities with metabolic pathways in Parkinsonian patients.

Dousa MK, Weinshilboum RM, Muenter MD, Offord KP, Decker PA, Tyce GM.

J Neural Transm (Vienna). 2003 Aug;110(8):899-910.

PMID:
12898345
16.

3-D-conformal radiation therapy for pediatric giant cell tumors of the skull base.

Hug EB, Muenter MW, Adams JA, de Vries A, Rosenberg AE, Munzenrider JE.

Strahlenther Onkol. 2002 May;178(5):239-44.

PMID:
12082682
17.

Conformal proton radiation therapy for pediatric low-grade astrocytomas.

Hug EB, Muenter MW, Archambeau JO, DeVries A, Liwnicz B, Loredo LN, Grove RI, Slater JD.

Strahlenther Onkol. 2002 Jan;178(1):10-7.

PMID:
11977386
18.

Neuropathology of two members of a German-American kindred (Family C) with late onset parkinsonism.

Wszolek ZK, Gwinn-Hardy K, Wszolek EK, Muenter MD, Pfeiffer RF, Rodnitzky RL, Uitti RJ, McComb RD, Gasser T, Dickson DW.

Acta Neuropathol. 2002 Apr;103(4):344-50. Epub 2001 Dec 8.

PMID:
11904753
19.

Tumor angiogenesis of low-grade astrocytomas measured by dynamic susceptibility contrast-enhanced MRI (DSC-MRI) is predictive of local tumor control after radiation therapy.

Fuss M, Wenz F, Essig M, Muenter M, Debus J, Herman TS, Wannenmacher M.

Int J Radiat Oncol Biol Phys. 2001 Oct 1;51(2):478-82.

PMID:
11567824
20.
21.

Distinctive neuropathology revealed by alpha-synuclein antibodies in hereditary parkinsonism and dementia linked to chromosome 4p.

Gwinn-Hardy K, Mehta ND, Farrer M, Maraganore D, Muenter M, Yen SH, Hardy J, Dickson DW.

Acta Neuropathol. 2000 Jun;99(6):663-72.

PMID:
10867800
22.

Motor unit changes in sporadic idiopathic Parkinson's disease.

Caviness JN, Smith BE, Stevens JC, Adler CH, Caselli RJ, Reiners CA, Hentz JG, Muenter MD.

Mov Disord. 2000 Mar;15(2):238-43.

PMID:
10752572
23.

Electrophysiological observations in hereditary parkinsonism-dementia with Lewy body pathology.

Caviness JN, Gwinn-Hardy K, Adler CH, Muenter MD.

Mov Disord. 2000 Jan;15(1):140-5.

PMID:
10634254
24.

L-dopa slows the progression of familial parkinsonism.

Gwinn-Hardy K, Evidente VG, Waters C, Muenter MD, Hardy J.

Lancet. 1999 May 29;353(9167):1850-1. No abstract available.

PMID:
10359414
25.

A chromosome 4p haplotype segregating with Parkinson's disease and postural tremor.

Farrer M, Gwinn-Hardy K, Muenter M, DeVrieze FW, Crook R, Perez-Tur J, Lincoln S, Maraganore D, Adler C, Newman S, MacElwee K, McCarthy P, Miller C, Waters C, Hardy J.

Hum Mol Genet. 1999 Jan;8(1):81-5.

PMID:
9887334
26.

Long-term follow-up of levodopa responsiveness in generalized dystonia.

Dewey RB Jr, Muenter MD, Kishore A, Snow BJ.

Arch Neurol. 1998 Oct;55(10):1320-3.

PMID:
9779659
27.

Hereditary form of parkinsonism--dementia.

Muenter MD, Forno LS, Hornykiewicz O, Kish SJ, Maraganore DM, Caselli RJ, Okazaki H, Howard FM Jr, Snow BJ, Calne DB.

Ann Neurol. 1998 Jun;43(6):768-81.

PMID:
9629847
28.

Exclusion of genetic linkage to 4q21-23 and 17q21 in a family with Lewy body parkinsonism.

Hardy J, Pérez-Tur J, Baker M, Farrer M, Crook R, Hutton M, Johnson WG, Gwinn K, Muenter M, Rocca WA, Maraganore D.

Am J Med Genet. 1998 Mar 28;81(2):166-71.

PMID:
9613857
29.

Cortical myoclonus in levodopa-responsive parkinsonism.

Caviness JN, Adler CH, Newman S, Caselli RJ, Muenter MD.

Mov Disord. 1998 May;13(3):540-4.

PMID:
9613750
30.

Early cinematographic cases of postencephalitic parkinsonism and other movement disorders.

Evidente VG, Gwinn KA, Caviness JN, Muenter M, Mulder DW.

Mov Disord. 1998 Jan;13(1):167-9. No abstract available.

PMID:
9452345
31.
32.

Adjunctive cabergoline therapy of Parkinson's disease: comparison with placebo and assessment of dose responses and duration of effect.

Ahlskog JE, Wright KF, Muenter MD, Adler CH.

Clin Neuropharmacol. 1996 Jun;19(3):202-12.

PMID:
8726539
33.

Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease.

Hutton JT, Koller WC, Ahlskog JE, Pahwa R, Hurtig HI, Stern MB, Hiner BC, Lieberman A, Pfeiffer RF, Rodnitzky RL, Waters CH, Muenter MD, Adler CH, Morris JL.

Neurology. 1996 Apr;46(4):1062-5.

PMID:
8780092
34.

Skin lesion with a fatal neurologic outcome (Degos' disease)

Subbiah P, Wijdicks E, Muenter M, Carter J, Connolly S.

Neurology. 1996 Mar;46(3):636-40.

PMID:
8618659
35.
36.

Aphysiologic performance on dynamic posturography.

Cevette MJ, Puetz B, Marion MS, Wertz ML, Muenter MD.

Otolaryngol Head Neck Surg. 1995 Jun;112(6):676-88.

PMID:
7777351
37.

Fluctuating Parkinson's disease. Treatment with the long-acting dopamine agonist cabergoline.

Ahlskog JE, Muenter MD, Maraganore DM, Matsumoto JY, Lieberman A, Wright KF, Wheeler K.

Arch Neurol. 1994 Dec;51(12):1236-41.

PMID:
7986180
38.

A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease.

Olanow CW, Fahn S, Muenter M, Klawans H, Hurtig H, Stern M, Shoulson I, Kurlan R, Grimes JD, Jankovic J, et al.

Mov Disord. 1994 Jan;9(1):40-7.

PMID:
8139604
39.

Levodopa therapy and survival in idiopathic Parkinson's disease: Olmsted County project.

Uitti RJ, Ahlskog JE, Maraganore DM, Muenter MD, Atkinson EJ, Cha RH, O'Brien PC.

Neurology. 1993 Oct;43(10):1918-26.

PMID:
8413948
40.

Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa.

Lieberman A, Imke S, Muenter M, Wheeler K, Ahlskog JE, Matsumoto JY, Maraganore DM, Wright KF, Schoenfelder J.

Neurology. 1993 Oct;43(10):1981-4.

PMID:
8105422
41.

Dopamine agonist treatment of fluctuating parkinsonism. D-2 (controlled-release MK-458) vs combined D-1 and D-2 (pergolide)

Ahlskog JE, Muenter MD, Bailey PA, Stevens PM.

Arch Neurol. 1992 May;49(5):560-8.

PMID:
1580821
42.

Treatment of essential tremor with methazolamide.

Muenter MD, Daube JR, Caviness JN, Miller PM.

Mayo Clin Proc. 1991 Oct;66(10):991-7.

PMID:
1921495
43.

Parkinson's disease monotherapy with controlled-release MK-458 (PHNO): double-blind study and comparison to carbidopa/levodopa.

Ahlskog JE, Muenter MD, Bailey PA, Miller PM.

Clin Neuropharmacol. 1991 Jun;14(3):214-27.

PMID:
1676932
44.

An unusual cause of recurrent chorea.

Caviness JN, Muenter MD.

Mov Disord. 1991;6(4):355-7.

PMID:
1661846
45.

An examination of male-female differences in progression and mortality of Parkinson's disease.

Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD.

Neurology. 1990 May;40(5):763-6.

PMID:
2330103
46.

MAO and L-dopa treatment of Parkinson's disease.

Tyce GM, Dousa MK, Muenter MD.

J Neural Transm Suppl. 1990;29:233-9.

PMID:
2358803
47.

Effect of age at onset on progression and mortality in Parkinson's disease.

Diamond SG, Markham CH, Hoehn MM, McDowell FH, Muenter MD.

Neurology. 1989 Sep;39(9):1187-90.

PMID:
2771070
48.

Pergolide: long-term use in Parkinson's disease.

Ahlskog JE, Muenter MD.

Mayo Clin Proc. 1988 Oct;63(10):979-87.

PMID:
3050301
49.

Treatment of Parkinson's disease with pergolide: a double-blind study.

Ahlskog JE, Muenter MD.

Mayo Clin Proc. 1988 Oct;63(10):969-78.

PMID:
3050300
50.

PHNO [(+)-4-propyl-9-hydroxynaphthoxazine]: a new and effective anti-Parkinson's disease agent.

Muenter MD, Ahlskog JE, Bell G, McManis P.

Neurology. 1988 Oct;38(10):1541-5.

PMID:
2901697

Supplemental Content

Loading ...
Support Center